Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Assembly Biosciences Inc

ASMB ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$36.60

▲ +1.30%

Market Cap $745.20M · Vol 59.91K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$745.20M

Small Cap

Div Yield

N/A

EPS Growth

-280.91%

YoY

RSI (14)

77.53

Momentum

Beta

1.12

vs Market

52W High

$39.64

7.66% below

52W Low

$20.27

80.56% above

Volume

59.91K

Avg 73.75K

P/B

2.61

Price-to-book

ROE

N/A

Return on equity

Free Float

72.28%

Public shares

Shariah Compliance8 STANDARDS

✗ Assembly Biosciences Inc (ASMB) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ASMB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.43%

+38.43%

+51.80%

+22.86%

YTD

+7.62%

+57.01%

+221.56%

-6.44%

Financials & Valuation

TTM · Annual

Total Revenue	$72.30M
Net Income	$-6,122,000.00
Revenue Growth (YoY)	+38.94%
Gross Margin	100.00%
Operating Margin	-16.76%
Net Profit Margin	-8.47%
ROE	N/A
ROA · ROIC	-3.25% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.27
P/B	2.61
P/FCF	N/A
EPS Growth	-280.91%
Outstanding Shares	20.36M

Technical Indicators

50-Day SMA	$29.18
200-Day SMA	$29.31
RSI (14)	77.53
Beta	1.12
52-Week High	$39.64
52-Week Low	$20.27

Volume Today	59.91K
Avg Daily Volume (30D)	73.75K
Relative Volume	0.81x
Volatility (10D)	37.12
Volatility (30D)	60.31
Free Float	72.28%

Analyst Consensus

STRONG BUY

Current Price $36.60

Mean Target $52.67

52W Low$20.27 52W High$39.64

Current

Target

$20.27 $39.64

Current Analyst target

+43.90% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001T9BMW0

ISINUS0453962070

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% RVMD Revolution Medicines Inc -0.40% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66%

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).